The Structural Basis of Cryptosporidium-Specific IMP Dehydrogenase Inhibitor Selectivity by MacPherson, Iain S. et al.
The Structural Basis of Cryptosporidium-Specific IMP
Dehydrogenase Inhibitor Selectivity
Iain S. MacPherson†, Sivapriya Kirubakaran†, Suresh Kumar Gorla†, Thomas V. Riera¥, J.
Alejandro D'Aquino¥, Minjia Zhang†, Gregory D. Cuny§, and Lizbeth Hedstrom†,¶
†Department of Biology, Brandeis University, MS009, 415 South St. Waltham, MA 02454
¥Department of Biochemistry, Brandeis University, MS009, 415 South St. Waltham, MA 02454
¶Department of Chemistry, Brandeis University, MS009, 415 South St. Waltham, MA 02454
§Laboratory for Drug Discovery in Neurodegeneration, Brigham & Women's Hospital, Harvard
Medical School, 65 Landsdowne Street, Cambridge, MA 02139
Cryptosporidium spp. are a major cause of the “vicious cycle” of diarrhea and malnutrition in
the developing world and a potential bioterrorism agent 1,2. This disease is prolonged and life-
threatening in immuno-compromised patients. Currently no effective therapy exists for
Cryptosporidium infections. Theparasite obtains guanine nucleotides via a streamlined
pathway that requires inosine 5’-monophosphate dehydrogenase (IMPDH) 3-5. Curiously, the
gene encoding CpIMPDH appears to have been obtained from a bacteria via lateral gene
transfer 6,7; we have exploited this unexpected divergence of parasite and host enzymes to
identify CpIMPDH-specific inhibitors in a high throughput screen 8. Here we report x-ray
crystal structures of CpIMPDH that explain the selectivity of one inhibitor series and use this
information to design more potent and selective analogs.
Recombinant CpIMPDH was purified as described previously 9 and crystallized using the
hanging drop vapor diffusion method. Protein solution (4 mg/mL IMPDH, 50 mM Tris-HCl,
pH 7.5, 150 mM KCl, 5% glycerol and 2 mM DTT) was mixed with well solution (34% PEG
4000, 25 mM sodium acetate and 100 mM Tris-HCl, pH 8.5) in a 1:1 ratio. Data were collected
from a single crystal at 100K at beamline 8-BM at Advanced Photon Source (Argonne National
Laboratory, Argonne, IL). The crystals had the symmetry of space group P21212. The
asymmetric unit contains one tetramer, which is the active form of IMPDH12. The structure
was solved to 3.2 Å resolution (R = 27%, Rfree = 33%) by molecular replacement using the
structure of IMPDH from Borrelia burgdorferi (PDB accession 1EEP10) as a search
model11. Only 301 of 400 residues are visible in the most structured monomer; the disordered
regions include catalytically important segments 214-222, 299-333 and 380-400 as well as
residues 92-122, which are not required for enzymatic activity 12. Unfortunately, we were
unable to improve this crystal form. This structure has been deposited in the PDB (3FFS).
To facilitate crystallization, residues 90-134 were replaced with SerGlyGly11; this
modification has no effect on enzymatic activity (Figure S1). A crystallization screen was
performed in the presence of IMP and various inhibitors that emerged from initial evaluation
of the SAR. Compound C64 was a particularly attractive candidate for crystallization because
of its improved potency relative to the parent compound C and the presence of a bromine atom
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which would allow the two aromatic groups to be easily distinguished (Table 1). Crystals were
obtained in the presence of saturating concentrations of inhibitor C64 (20 μM), IMP (1 mM),
100 mM sodium acetate, pH 4.6, 20 mM CaCl2 and 30% MPD under oil. These crystals had
the symmetry of space group P21 with two tetramers in the asymmetric unit. Data were
collected at a wavelength of 0.9194 Å, enabling the simultaneous collection of bromine k-edge
anomalous dispersion data. The structure was solved by molecular replacement to 2.8 Å
resolution using the native CpIMPDH structure as the starting model (R = 26.6%, Rfree =
22.4%).
While the overall structure of the E•IMP•C64 complex is similar to that of the unliganded
enzyme, several additional residues are observed. Residues 214-226, which include the
catalytic Cys219, are observed in most of the monomers, as are parts of the active site flap
(residues 302-330) containing the characteristic ArgTyr motif 12. Lastly, the SerGlyGly linker
is visible in all monomers. Electron density for IMP is observed in all eight monomers.
Monomers B, D and H contained extra electron density near IMP (Figure 1). Bromine k-edge
anomalous dispersion maps allowed the unambiguous assignment of the bromine atom in
C64 in all three monomers. The rest of C64 was modeled into the remaining electron density;
similar conformations of C64 are obtained in all three monomers. This structure has been
deposited in the PDB (3KHJ).
Surprisingly, C64 binds in an unprecedented fashion. Inhibitors of human IMPDH2 such as
mycophenolic acid and merimepodib bind in the nicotinamide subsite, stacking against the
purine ring of IMP in a parallel fashion, and extend either into the NAD site or into a pocket
adjacent the active site but within the same monomer 12-14. In contrast, the thiazole ring of
C64 stacks against the purine ring of IMP perpendicularly, and the remainder of C64 extends
across the subunit interface into a pocket in the adjacent monomer, where the bromoaniline
moiety interacts with Tyr358’ (where ’ denotes a residue from the adjacent subunit; Figure 2).
This residue forms a hydrogen bonding network involving Glu329, Ser354, Thr221 and
possibly the amide nitrogen of C64 (Figure 2). Ser22’, Pro26’, Ala165, Gly357’ form the
remainder of the inhibitor binding pocket. With the exception of Thr221, all of these residues
are different in human IMPDHs (Figure 2). Thus these interactions account for the selectivity
of C64 for CpIMPDH over human IMPDHs.
The structure also revealed the presence of a cavity adjacent to the bromoaniline moiety (Figure
1), which suggested that more potent inhibitors might be created by increasing the bulk of this
substituent. Additional benzimidazole based inhibitors were prepared by condensing o-
phenylenediamine 1 with thiazole carboxaldehydes 2 in the presence of the oxidizing reagent
sodium metabisulfite 3 (Scheme 1)15. The resulting 2-substituted benzimidazoles 4 were then
coupled with different bromoacetylamides 5 under mild basic conditions to give the new
analogs 6 (Table 1).
The CpIMPDH inhibitory activity of the compounds was assessed by monitoring the
production of NADH by fluorescence (Table 1)16. Replacing the p-MeO of the parent
compound C with Cl or Br increased potency by 10-fold (C10) and 20-fold (C14), respectively,
as has been similarly observed with another inhibitor series.16 To fill the cavity observed in
the crystal structure, the para-substituted aniline group was replaced with 3,4-dichloroaniline
(C86) or 2-naphthylamine (C90); the addition of a second Cl improved potency by a factor of
2, while fusing an additional aromatic ring increased potency by a factor of 8. Similar trends
were observed when the thiazole ring was attached at the 2-position (C61, C64, C84 and
C90). None of the compounds displayed significant inhibitory activity against human
IMPDH2. The best CpIMPDH inhibitor, C90, has an IC50 = 7.4 nM with selectivity >103 for
the parasite enzyme.
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In conclusion, the crystal structure of CpIMPDH reveals the structural basis of inhibitor
selectivity and a strategy for further optimization. This information was used to design more
potent and selective inhibitors of CpIMPDH that are potential lead compounds for the treatment
of cryptosporidiosis.
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Figure 1.
Co-crystallized structure of CpIMPDH (light gray) with IMP (salmon) and C64 (slate) shown
from two different perspectives. The electron density map prior to C64 modeling with
coefficients 2Fo-Fc is contoured to 1σ and shown as a slate cage. The electron density map
prior to C64 modeling with coefficients Fo-Fc is contoured to 3σ and shown as a green cage.
Bromine K-edge peak anomalous dispersion map is contoured to 4σ and shown as a red cage.
The red and blue surfaces denote regions of negative and positive electrostatic potential,
respectively.
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Figure 2.
The C64 binding pocket of CpIMPDH (green) superposed with human IMPDH2 (cyan).
CpIMPDH residues are labeled.
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Table 1
Inhibition of CpIMPDH and hIMPDH2.
Scheme 1. Synthesis of inhibitors.
Cmpd R1 R2
IC50 (nM)
CpIMPDH hIMPDH2
C 4-OMePh 1200 ± 200a ≥200,000a,b
C10 4-ClPh 120 ± 40 ≥20,000c
C14 4-BrPh 60 ± 30 ≥20,000c
C86 2,3-Di-ClPh 30 ± 10 ≥40,000d
C90 2-Naph 7 ± 4 ≥40,000d
C61 4-ClPh 30 ± 10 ≥40,000d
C64 4-BrPh 28 ± 9 ≥40,000d
C84 2,3-di-ClPh 18 ± 5 ≥8,000e
C97 2-Naph 8 ± 3 ≥40,000d
a
values from 8.
b≤20% inhibition at 50 μM
c≤20% inhibition at 5 μM
d≤ 10% inhibition at 5 μM
e≤ 20% inhibition observed at 2 μM.
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